{"prompt": "['Drug', 'Dose/Potency', 'Dose', 'Route of', 'Regimen/Treatment', 'Use', 'Frequency', 'Administration', 'Period', 'Lenvatinib', '20 mg', 'Daily', 'PO with', 'QD in 21 day cycles', 'Experimental', 'water', 'x 4 cycles', '5.2.1 Timing of Dose Administration', 'Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments', 'have been completed as detailed on the Trial Flow Chart (Section 6.0). Trial treatment may be', 'administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative', 'reasons.', 'All trial treatments will be administered on an outpatient basis.', '5.2.2 Lenvatinib', 'Lenvatinib will be administered with water orally once a day (with or without food) in 21-day', 'cycles at approximately the same time each day. Treatment cycles will be counted continuously', 'regardless of dose interruptions. On Day 1 of each cycle, it will be administered approximately 1', 'hour after completion of pembrolizumab administration.', 'Lenvatinib will be provided as 4 mg and 10 mg capsules. Lenvatinib is formulated with calcium', 'carbonate, mannitol, microcrystalline cellulose, hydroxypropyleellulose low-substituted', 'hydroxypropylcellulose, and talc.', \"Lenvima is the mesylate salt of lenvatinib. Its chemical name is 4-[3-chloro-4-(N'.\", 'cyclopropylureido)phenoxy]-7-methoxyquinoline-6 carboxamide methanesulfonate. The', 'molecular formula is C21H19CIN404.CH403S and the molecular weight is 522.96. The', 'chemical structure of lenvatinib mesylate is:', 'H3CO', 'N', 'H2N', 'O', 'O', 'H3C-SO3H', 'O', 'N', 'N', 'H', 'H', 'CI', 'Page 16', 'Version Date: 05/08/2020']['5.2.2.1 Criteria for Interruption of Treatment, Dose Reduction and Resumption of', 'Treatment', 'Lenvatinib dose reduction and interruption for subjects who experience lenvatinib-related', 'toxicity will be in accordance with the guidelines provided in Table 3. Once the dose has been', 'reduced, it may not be increased at a later date.', 'As this is a neoadjuvant study culminating in the potentially curative surgery, we will allow no', 'more than one dose-limiting toxicity for each drug including lenvatinib and pembrolizumab. The', 'lenvatinib dose may be lowered once to 14 mg. If the patient has a 2nd occurrence (same or new', 'toxicity) of an intolerable grade 2 or any grade 3-4 event, the patient should stop both study', 'drugs immediately and proceed with nephrectomy at least 7 days after the last dose of lenvatinib.', 'Those patients will be in-evaluable and be replaced.', 'Page 17', 'Version Date: 05/08/2020']['For management of hypertension and proteinuria, refer to main protocol text for instructions', 'before consulting the table below, as appropriate.', 'Table 3. Dose Modifications for Lenvatinib Treatment-Related Toxicity', 'Lenvatinib Treatment-Related', 'During Therapy', 'Adjusted Dose', 'Toxicity', 'a,b', 'Grade 1, Tolerable Grade 2', 'Continue treatment', 'No change', 'c,d', 'g', 'Intolerable Grade 2 and Grade 3', '1st occurrence', 'Interrupt lenvatinib until resolved to', 'Reduce lenvatinib dose to', 'tolerable Grade 2 or Grade 0-1', '14mg', '2nd occurrence (same toxicity or', 'Discontinue lenvatinib and pembrolizumab and proceed to nephrectomy at', 'new toxicity)', 'least 7 days after the last dose of lenvatinib', 'e,f', 'Grade 4:', 'Discontinue lenvatinib and pembrolizumab and proceed to nephrectomy at least 7 days after the last dose of', 'lenvatinib', 'a.', 'An interruption of lenvatinib treatment for more than 21 days (due to lenvatinib treatment-related toxicities) will require a', 'discussion with the sponsor before treatment can be resumed.', 'b.', 'Excluding alopecia. Initiate optimal medical management for nausea, vomiting, hypothyroidism, hypertension and/or diarrhea', 'prior to any lenvatinib interruption or dose reduction. For treatment-related hypertension, refer to Management of Hypertension', '(Section 5.2.2.2.1) for dose modification guidelines.', 'c.', 'Applicable only to Grade 2 toxicities judged by subject and/or physician to be intolerable.', 'd.', 'Obese subjects with weight loss do not need to return to the baseline weight or 10% of baseline weight (i.e., Grade 1 weight loss).', 'These subjects will restart the study drug(s) at a lower dose once their weight remains stable for at least 1 week and they reached', 'the normal BMI (if the weight loss occurred but it is still above normal BMI, they can restart the study treatment at a lower dose', 'once the weight has been stable for at least 1 week). Normal BMI should be used as the new baseline for further dose reductions.', 'e.', 'Excluding laboratory abnormalities judged to be non-life-threatening, in which case manage as Grade 3.', 'f.', 'For asymptomatic Grade >3 elevations of amylase and lipase, treatment may resume per investigator discretion.', 'g.', 'Refer to Table 4 for dose adjustments', 'General guidelines for holding periods of lenvatinib due to procedures:', 'For minor procedures, lenvatinib should be stopped 2 days before the procedure and restarted 2', 'days after, once there is evidence of adequate healing and no risk of bleeding. Needle biopsies', '(fine needle aspirations and core needle aspiration) are usually considered minor procedures.', 'For major procedures, lenvatinib should be stopped 1 week (5 half-lives) before the procedure', 'and then restarted once there is clear wound healing and no risk of bleeding, but at least 1 week', 'after the procedure. It is up to the investigator to determine if it is a major or minor procedure.', 'Usually a major procedure implies general anesthesia.', 'Page 18', 'Version Date: 02/09/2020']\n\n###\n\n", "completion": "END"}